Literature DB >> 3543401

Expression of the art gene protein of human T-lymphotropic virus type III (HTLV-III/LAV) in bacteria.

W C Goh, J G Sodroski, C A Rosen, W A Haseltine.   

Abstract

Human T-lymphotropic virus type III (HTLV-III/LAV or HIV) contains a gene designated art (anti-repressor transactivator). Here, we report the expression of the art gene product in bacteria and show that the 20-kilodalton (kDa) bacterially expressed art protein is recognized by serum of a patient. The bacterially synthesized art protein competed in an immunological reaction with a 20-kDa protein produced in HTLV-III/LAV-infected lymphocytes. Antiserum to a synthetic oligopeptide corresponding to a sequence in the second exon of the art gene also precipitated the 20-kDa protein in HTLV-III/LAV-infected cells. These results demonstrate that the 20-kDa art gene product is expressed in cell lines that produce HTLV-III/LAV virions.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3543401      PMCID： PMC253996          DOI： 10.1128/JVI.61.2.633-637.1987

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  20 in total

1.  A second post-transcriptional trans-activator gene required for HTLV-III replication.

Authors:  J Sodroski; W C Goh; C Rosen; A Dayton; E Terwilliger; W Haseltine
Journal:  Nature       Date:  1986 May 22-28       Impact factor: 49.962

2.  The use of pKc30 and its derivatives for controlled expression of genes.

Authors:  M Rosenberg; Y S Ho; A Shatzman
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

3.  HTLV-III infection in brains of children and adults with AIDS encephalopathy.

Authors:  G M Shaw; M E Harper; B H Hahn; L G Epstein; D C Gajdusek; R W Price; B A Navia; C K Petito; C J O'Hara; J E Groopman
Journal:  Science       Date:  1985-01-11       Impact factor: 47.728

4.  Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS.

Authors:  M G Sarngadharan; M Popovic; L Bruch; J Schüpbach; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

5.  Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

Authors:  H C Lane; H Masur; L C Edgar; G Whalen; A H Rook; A S Fauci
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

6.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

7.  Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency.

Authors:  M S Gottlieb; R Schroff; H M Schanker; J D Weisman; P T Fan; R A Wolf; A Saxon
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

8.  Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions.

Authors:  F P Siegal; C Lopez; G S Hammer; A E Brown; S J Kornfeld; J Gold; J Hassett; S Z Hirschman; C Cunningham-Rundles; B R Adelsberg
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

9.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.

Authors:  J A Levy; A D Hoffman; S M Kramer; J A Landis; J M Shimabukuro; L S Oshiro
Journal:  Science       Date:  1984-08-24       Impact factor: 47.728
View more
  9 in total

1.  Phosphorylation of the rev gene product of human immunodeficiency virus type 1.

Authors:  J Hauber; M Bouvier; M H Malim; B R Cullen
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

2.  The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors.

Authors:  R J Mervis; N Ahmad; E P Lillehoj; M G Raum; F H Salazar; H W Chan; S Venkatesan
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

3.  Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus.

Authors:  C A Rosen; E Terwilliger; A Dayton; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

4.  Subcellular localization of the human immunodeficiency virus trans-acting art gene product.

Authors:  B R Cullen; J Hauber; K Campbell; J G Sodroski; W A Haseltine; C A Rosen
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

5.  Cleavage of procaryotically expressed human immunodeficiency virus fusion proteins by factor Xa and application in western blot (immunoblot) assays.

Authors:  S Ellinger; R Glockshuber; G Jahn; A Plückthun
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

6.  Human immunodeficiency virus type 1 has an additional coding sequence in the central region of the genome.

Authors:  Z Matsuda; M J Chou; M Matsuda; J H Huang; Y M Chen; R Redfield; K Mayer; M Essex; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

7.  Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles.

Authors:  C Lavallée; X J Yao; A Ladha; H Göttlinger; W A Haseltine; E A Cohen
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Human immunodeficiency viral long terminal repeat is functional and can be trans-activated in Escherichia coli.

Authors:  F Kashanchi; C Wood
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

9.  A tripartite HIV-1 tat-env-rev fusion protein.

Authors:  J Salfeld; H G Göttlinger; R A Sia; R E Park; J G Sodroski; W A Haseltine
Journal:  EMBO J       Date:  1990-03       Impact factor: 11.598
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.